EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
The paper analyzes the data available in the literature on the mechanisms of action of certolizumab pegol (CZP), a new tumor necrosis factor-α (TNF-α) inhibitor for the treatment of active psoriatic arthritis (PsA). It describes the unique molecular structure of the drug and its mechanism of action...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2015-10-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2132 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849400073736159232 |
|---|---|
| author | T. V. Korotaeva E. Yu. Loginova |
| author_facet | T. V. Korotaeva E. Yu. Loginova |
| author_sort | T. V. Korotaeva |
| collection | DOAJ |
| description | The paper analyzes the data available in the literature on the mechanisms of action of certolizumab pegol (CZP), a new tumor necrosis factor-α (TNF-α) inhibitor for the treatment of active psoriatic arthritis (PsA). It describes the unique molecular structure of the drug and its mechanism of action and shows that CZP effectively inhibits TNF-α, without inducing cell apoptosis, and has also low immunogenicity. The results of the RAPID-PsA clinical trial of CZP are discussed. Treatment with CZP at different doses promptly suppresses the manifestations of both arthritis and psoriasis. There is evidence that CZP therapy prevents joint erosion formation in patients with active disease in particular. It is concluded that CZP is a promising drug to treat active PsA; however, it is necessary to conduct further fundamental and clinical studies of this class of drugs against certain cytokines. |
| format | Article |
| id | doaj-art-963e9efce0734932863e5e23321adeb7 |
| institution | Kabale University |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2015-10-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-963e9efce0734932863e5e23321adeb72025-08-20T03:38:11ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922015-10-0153555355710.14412/1995-4484-2015-553-5572015EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIST. V. Korotaeva0E. Yu. Loginova1V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522The paper analyzes the data available in the literature on the mechanisms of action of certolizumab pegol (CZP), a new tumor necrosis factor-α (TNF-α) inhibitor for the treatment of active psoriatic arthritis (PsA). It describes the unique molecular structure of the drug and its mechanism of action and shows that CZP effectively inhibits TNF-α, without inducing cell apoptosis, and has also low immunogenicity. The results of the RAPID-PsA clinical trial of CZP are discussed. Treatment with CZP at different doses promptly suppresses the manifestations of both arthritis and psoriasis. There is evidence that CZP therapy prevents joint erosion formation in patients with active disease in particular. It is concluded that CZP is a promising drug to treat active PsA; however, it is necessary to conduct further fundamental and clinical studies of this class of drugs against certain cytokines.https://rsp.mediar-press.net/rsp/article/view/2132psoriatic arthritisbiological agentscertolizumab pegol |
| spellingShingle | T. V. Korotaeva E. Yu. Loginova EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS Научно-практическая ревматология psoriatic arthritis biological agents certolizumab pegol |
| title | EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS |
| title_full | EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS |
| title_fullStr | EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS |
| title_full_unstemmed | EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS |
| title_short | EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS |
| title_sort | efficacy of certolizumab pegol in the treatment of psoriatic arthritis |
| topic | psoriatic arthritis biological agents certolizumab pegol |
| url | https://rsp.mediar-press.net/rsp/article/view/2132 |
| work_keys_str_mv | AT tvkorotaeva efficacyofcertolizumabpegolinthetreatmentofpsoriaticarthritis AT eyuloginova efficacyofcertolizumabpegolinthetreatmentofpsoriaticarthritis |